Brief: AB Science/Masitinib: U.S FDA Authorizes Start Confirmatory Phase 3 Study In Treatment Of Alzheimer's

AB Science SA

21/11/2022 17:12

Nov 21 (Reuters) - Ab Science Sa  ABS.PA :
    * AB SCIENCE RECEIVES U.S. FOOD AND DRUG ADMINISTRATION
(FDA)
AUTHORIZATION TO INITIATE CONFIRMATORY PHASE 3 CLINICAL STUDY
WITH MASITINIB IN THE TREATMENT OF ALZHEIMER’S DISEASE
    * STUDY WILL ENROLL 600 PATIENTS WITH CONFIRMED CLINICAL
DIAGNOSIS
OF MILD AND MODERATE ALZHEIMER'S DISEASE
    * OBJECTIVE OF STUDY AB21004 IS TO CONFIRM RESULTS FROM
FIRST
PHASE 2B/3 STUDY, AB09004

Source text for Eikon:  ID:nGNX1hjvq 
Further company coverage:  ABS.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))